ALKS Alkermes Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALKS
  4. Earnings
?
Relative Growth: Rel. Growth: 21
Relative Strength: Rel. Strength: 83
Relative Valuation: Rel. Valuation: 23
Relative Profitability: Rel. Profitability: 66

EPS in 2026 (TTM): $0.93

Last Report Period Date: Mar 31, 2026

Currently, ALKS's current EPS stands at $0.93, according to the most recent financial reports. For the year 2025, ALKS reported a per-share earnings of $1.47, which marks a decrease compared to the EPS of $2.22 recorded in 2024. ALKS recorded an EPS of -$0.4 for the quarterly period ending on Mar 31, 2026.

ALKS earnings history

Historical annual and quarterly earnings per share (EPS) data for Alkermes
EPS (TTM)
$0.93
EPS Growth YoY (Quarterly)
-385.7%
EPS (Quarterly)
-$0.4
EPS Growth (Quarterly)
-233.3%

In 2025, Alkermes's EPS was $1.47, a decrease of 33.8% from $2.22 in 2024. For the fiscal quarter that ended on Mar 31, 2026, the per-share earnings was -$0.4, reflecting a 385.7% decline compared to the same quarter a year earlier. For the twelve months ending March 2026, the EPS is $0.93. For the year 2024, the yearly earnings per share was $2.22, marking an increase of 3.7% compared to 2023.

ALKS earnings chart

ALKS EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-385.7%
EPS growth YoY
-33.8%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

Alkermes has registered a decrease in earnings per share of 385.7% over the past 12 months (YoY, quarterly).

ALKS Earnings Waterfall

Breakdown of revenue, profit and net income for Alkermes

ALKS Earnings vs Peers

What are the earnings of ALKS compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
BMY Bristol Myers Squibb Co 15.86 178.7% 5.3% N/A
PFE Pfizer Inc 19.61 -3.5% -37.4% -3.7%
NVS Novartis AG 21.14 21.8% 31.2% 15.2%
TEVA Teva Pharmaceutical Industries Ltd 24.93 184.8% N/A N/A
JNJ Johnson & Johnson 26.13 90.6% 17.7% 14.8%
AZN Astrazeneca plc 27.09 45.4% 46% 22%
ALKS Alkermes plc 46.63 -33.8% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.